Drug Combination Details
| General Information of the Combination (ID: C34743) | |||||
|---|---|---|---|---|---|
| Name | Ginsenoside Rg3 NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PECAM1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | 0.2 mL Lewis lung carcinoma cell suspensions (1*107/mL) were injected subcutaneously into the armpit of right anterior superior limbs of female C57BL/6 mice. | |||||
| Experimental
Result(s) |
Ginsenoside Rg3 combined with gemcitabine may significantly inhibit angiogenesis and growth of lung cancer and improve survival and quality of life of tumor-bearing mice. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer. 2009 Jul 23;9:250. | |||
